![Teresa Lama](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Teresa Lama worked as a Senior Scientist-Medicinal Chemistry at Mimetogen Pharmaceuticals, Inc. from 2007 to 2015.
Prior to that, she worked as a Principal at Università degli Studi di Napoli Federico II.
Dr. Lama received a graduate and doctorate degree from Università degli Studi di Napoli Federico II.
Precedenti posizioni note di Teresa Lama
Società | Posizione | Fine |
---|---|---|
Mimetogen Pharmaceuticals, Inc.
![]() Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 01/09/2015 |
Università degli Studi di Napoli Federico II | Corporate Officer/Principal | - |
Formazione di Teresa Lama
Università degli Studi di Napoli Federico II | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Mimetogen Pharmaceuticals, Inc.
![]() Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Health Technology |
- Borsa valori
- Insiders
- Teresa Lama